Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Case Study: Successful Medical Device Launches with EvoLV's Consulting

Apr 13, 2025

Introduction to EvoLV's Consulting Services

In the competitive world of medical device manufacturing, launching a new product successfully can be a daunting task. Companies face numerous challenges, from regulatory compliance to market acceptance. EvoLV's Consulting has made a name for itself by offering expert guidance in navigating these complexities. This case study explores how EvoLV's expertise has facilitated successful product launches for medical device companies.

medical device

Understanding the Challenges

Launching a medical device involves more than just innovation. Companies must comply with stringent regulatory standards, which can vary significantly across regions. Additionally, the market for medical devices is highly competitive, requiring a strategic approach to stand out. EvoLV's Consulting recognizes these hurdles and provides tailored solutions to address them.

One of the key challenges is ensuring that the product meets all necessary safety and efficacy standards. EvoLV's team includes regulatory experts who work closely with clients to ensure compliance with agencies like the FDA and EMA. Their proactive approach helps avoid costly delays and ensures a smoother path to market entry.

Strategic Market Positioning

Another critical aspect of a successful launch is effective market positioning. EvoLV's Consulting employs a data-driven approach to identify target markets and craft compelling value propositions. Their strategy includes:

  • Conducting thorough market research to understand customer needs and preferences.
  • Developing a unique selling proposition (USP) that highlights the product's benefits.
  • Creating a comprehensive marketing plan that leverages multiple channels for maximum reach.
market research

Collaborative Product Development

EvoLV's Consulting believes in a collaborative approach to product development. By working closely with clients, they ensure that the final product aligns with market demands and customer expectations. This collaboration extends to:

  1. Regular feedback sessions with stakeholders.
  2. Iterative design processes that incorporate user feedback.
  3. Pilot testing in real-world environments to refine the product.

Such an approach not only enhances product quality but also builds trust with end-users, which is crucial for long-term success.

Case Study: A Proven Track Record

EvoLV's Consulting has a proven track record of successful medical device launches. One notable example is their collaboration with a startup developing a cutting-edge diagnostic tool. By leveraging EvoLV's expertise, the startup achieved:

  • Regulatory approval in record time.
  • A 30% increase in market share within the first year of launch.
  • Positive feedback from healthcare professionals and patients alike.
successful launch

Conclusion: Partnering for Success

EvoLV's Consulting stands out as a trusted partner for medical device companies looking to navigate the complexities of product launch. Their comprehensive services—from regulatory guidance to strategic marketing—ensure that clients not only meet but exceed their launch objectives. With EvoLV's support, companies can confidently enter the market and make a meaningful impact in the healthcare industry.

If you're preparing for a medical device launch, consider partnering with EvoLV's Consulting for expert guidance and proven results.